Office of the Chief Medical Officer

he Johnson & Johnson Office of the Chief Medical Officer (OCMO) is a global, functionally independent group responsible for leading safety and championing bioethical principles across Johnson & Johnson’s Pharmaceutical, Medical Device and Consumer Health sectors. Johnson & Johnson’s OCMO is constantly reviewing, monitoring and making decisions regarding the safety of our products through people-driven processes, initiatives and policies that are reinforced by a single medical safety standard, to which all our products are held.

Watch the Video

Scientific Excellence, Bioethics and Values-Driven Decision-Making

Learn More

Expanding Access to Our Investigational Medications

Learn More

Engaging with Patients & Consumers as Partners

Learn More

Making Healthcare Decisions Through a Bioethical Lens

Learn More

Innovating to Advance Health Outcomes for Patients & Consumers

Our Ethics- and Science-Driven Healthcare Initiatives

Safety Assessment of Johnson & Johnson Products

Within Johnson & Johnson’s Office of the Chief Medical Officer, safety assessment that is objective and science- and evidence-based is at the core of what we do and is built into every stage of our products’ life cycles—from development to post-launch. But just how do we do it?

ON NOW

The Power of Real-World Data to Enhance Safety

The Johnson & Johnson Office of the Chief Medical Officer (OCMO) believes in the collective power of real-world observational data to complement clinical trial findings, and in sharing our insights widely to accelerate important research and policy developments and improve health outcomes for people everywhere.

ON NOW

The Power of Real-World Data to Enhance Safety

The Yale Open Data Access Project

Sharing of clinical trial data is critical to the advancement of the science that is the foundation of medicine and public health. It furthers our understanding of diseases, expands the base of knowledge needed to develop new treatments and generates new insights and more complete evidence to enable better healthcare decisions for patients.

ON NOW

Decisions Guided Through a Bioethical Lens

Bioethics is an applied discipline that takes the principles of ethics and applies them to biological research, science and medicine. Adherence to bioethical principles, including transparency, integrity and respect for the rights and welfare of all persons, stems from Our Credo values and the commitment we make to our patients and consumers.

ON NOW

A photo of doctors talking about bioethics

Compassionate Use

ON NOW

A photo of a child receiving a vaccination in their right arm

CHILD: A Commitment to Children and Parents

Our commitment to the safety and well-being of children has been a cornerstone of Johnson & Johnson's work for over 130 years, and we are committed to continue improving medical innovation for children.

ON NOW

A photo of a mother and her son laughing

Featured

Every day, we work to put people first—from proactive and transparent medical safety surveillance, to groundbreaking real-world evidence applications, pediatric clinical research advancements, early access innovation and more.

Office of the Chief Medical Officer

Why Johnson & Johnson Is on a Mission to Make Treating Pediatric Patients Safer

For Baby Safety Month, we sat down with the company's Head of Pediatric Drug Development to learn about its industry-leading Child Health Innovation Leadership Department.

Read the Story

Office of the Chief Medical Officer

Preclinical Science: Driving Excellence in Safety at Johnson & Johnson

A Q&A with Gary Eichenbaum, Ph.D., Vice President, Preclinical Science and Safety, Office of the Chief Medical Officer, Johnson & Johnson.

Read the Story

A photo of Joanne Waldstreicher — Joanne Waldstreicher, M.D., Chief Medical Officer, Johnson & Johnson

Office of the Chief Medical Officer

How Johnson & Johnson Is Helping Patients Through Its Compassionate Use Program

The company's mission is to care for the world—one person at a time. Just ask Chief Medical Officer Joanne Waldstreicher, M.D., who's been leading the charge to improve the process by which very sick patients may apply for access to investigational medications.

Learn More

Johnson & Johnson Chief Medical Officers

Our Chief Medical Officers drive medical safety excellence and innovation across our Pharmaceuticals, Medical Devices and Consumer Products sectors.

Joanne Waldstreicher bio image_circle — Joanne Waldstreicher, M.D., Chief Medical Officer

Aran Maree, M.D., Chief Medical Officer, Pharmaceuticals

Jijo James, M.D., Chief Medical Officer, Medical Devices

Ed Kuffner, M.D., Chief Medical Officer, Consumer

In the News

News and highlights about the Office of the Chief Medical Officer.

Bioethics

How the Industry Is Addressing the Ethical Concerns of Incorporating Big Data into Health Care

ON NOW

A photo of a person typing on a computer keyboard

Clinical Trials

Overview and Experience of the YODA Project With Clinical Trial Data Sharing After 5 Years

ON NOW

Innovation

How Women at Johnson & Johnson Are Changing Healthcare As We Know It

ON NOW

Compassionate Use

Johnson & Johnson Expands Access to Investigational Medications Through Its CompAC Program

ON NOW

Innovation

The Yale Open Data Access Project: How Johnson & Johnson Is Leading the Way on Clinical Data Transparency

ON NOW

Bioethics

New York Times: Company Creates Bioethics Panel on Trial Drugs

ON NOW

Scientific Policies

Johnson & Johnson is committed to ethical decision-making and transparency to guide every decision we make. Read more for our scientific policies on sensitive topics.

Position on Human Pluripotent Stem Cell Research

June 11, 2020

These guidelines are to ensure that human pluripotent stem cell research conducted by Johnson & Johnson conforms to current international standards of scientific and ethical oversight, and that all scientists and employees of the Johnson & Johnson Family of Companies adhere to these ethical principles when conducting human pluripotent stem cell research.

Learn More
Ethical Code for the Conduct of Research and Development

June 11, 2020

Our Ethical Code for the Conduct of Research and Development is intended to complement our Credo by providing more specific standards of conduct and behavior for physicians, clinical research scientists and others who are responsible for medical aspects of research and development.

Learn More
Position on Clinical Trial Data Transparency

June 11, 2020

We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who prescribe them.

Learn More
Position on Compassionate Use & Pre-Approval Access

June 11, 2020

We follow five important principles when providing pre-approval access to investigational medicines to patients with serious diseases to access medicines not yet approved by regulatory health authorities.

Learn More

More From Johnson & Johnson

Innovation

The COVID-19 Data Plan: 3 Innovative Ways Johnson & Johnson Is Using Data Science to Fight the Pandemic

Tracking the spread of the virus in real time. Analyzing data to learn more about who's most vulnerable. These are just a couple of ways the company's data science team is helping inform how to respond to the pandemic.

ON NOW

Innovation

COVID-19 Update: Your Latest Questions About Johnson & Johnson's Investigational Vaccine Candidate Answered

With its Phase 3 clinical trial now fully enrolled, the Global Head of Research & Development at Janssen brings us up to speed on the progress of the company's vaccine candidate, including upcoming key milestones.

ON NOW